Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/34716
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Limitations to enhancing the speed of onset of antidepressants. Are rapid action antidepressants possible? |
Autor: | Artigas, Francesc CSIC ORCID | Palabras clave: | 5-HT1A receptors Antidepressants Clinical trials Pindolol Selective serotonin reuptake inhibitors (SSRIs) Serotonin |
Fecha de publicación: | ene-2001 | Editor: | John Wiley & Sons | Citación: | Human Psychopharmacology - Clinical and Experimental 16(1): 29-36 (2001) | Resumen: | Existing antidepressant treatments suffer from a limited efficacy and a slow onset of action. Some first-generation antidepressant drugs are still among the most effective treatments. Several neurobiological adaptive mechanisms are involved in the delayed action of antidepressants. Among these, a negative feed-back involving somatodendritic autoreceptors plays an important role in such delay. In the case of the SSRIs, the prevention of this effect with 5-HT1A autoreceptor antagonists enhances their effects at experimental level. Open-label and placebo-controlled trials with the mixed β-adrenoceptor/5-HT1A antagonist pindolol support that this agent reduces the latency to achieve a clinical improvement when used in combination with SSRIs. Displacement studies support that this action is mediated by its interaction with 5-HT1A receptors. The design of clinical trials for the evaluation of fast-acting antidepressants is critical. The use of loose criteria of response may result in a poor discriminating power. Conversely, stringent clinical criteria may be more helpful in revealing the differences between treatments. The data of a double-blind, placebo-controlled trial comparing fluoxetine plus placebo and fluoxetine plus pindolol suggests that the use of sustained response (i.e., one maintained until the end of the trial) is critical for the establishment of differences between treatments. Other factors, such as a placebo lead-in phase or the frequency of visits, appear to play a minor role. Overall, these data indicate that faster antidepressant drugs can be obtained through a better knowledge of their actions in CNS. | Versión del editor: | http://dx.doi.org/10.1002/hup.180 | URI: | http://hdl.handle.net/10261/34716 | DOI: | 10.1002/hup.180 | ISSN: | 0885-6222 | E-ISSN: | 1099-1077 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
23
checked on 08-may-2024
WEB OF SCIENCETM
Citations
23
checked on 24-feb-2024
Page view(s)
348
checked on 16-may-2024
Download(s)
108
checked on 16-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.